Chronic Lymphocytic Leukemia
December 2019 Issue
 
 
 

Nearly every major medical breakthrough over the past 50 years can be attributed to new discoveries that were made possible through meticulous biomedical research. Many diseases and conditions that previously took a heavy toll on patients in terms of both morbidity and mortality are now either treatable or preventable thanks in large part to painstaking research that expanded the frontiers of scientific knowledge and moved the most promising basic research developments into tangible health benefits through human clinical trails. Ongoing research is also the key that will open the door to additional major medical advances and breakthroughs in the future.

Our staff at Medifocus is committed to keeping our subscribers to the Medifocus Digest Alert on Chronic Lymphocytic Leukemia abreast of the latest new research developments that have recently been published in the medical literature for this condition. In this issue of the Digest Alert, you will find a focused list of hand-picked journal article references that represent the latest advances in basic and clinical research for Chronic Lymphocytic Leukemia. These articles represent the current state-of-the-art of the research that will hopefully lead to additional major advances and breakthroughs in the clinical management of Chronic Lymphocytic Leukemia. You can access the summaries of each article referenced below by simply clicking on the article Title.

We will continue to update you with the latest scientific and clinical developments through the Medifocus Digest Alert on Chronic Lymphocytic Leukemia every 3 months. Thank you for your ongoing subscription to this publication.

Elliot Jacob, Ph.D.
Vice-President - Content
Medifocus.com, Inc.



1:Reduced intensity conditioning regimens including alkylating chemotherapy do not alter survival outcomes after allogeneic hematopoietic cell transplantation in chronic lymphocytic leukemia compared to low-intensity non-myeloablative conditioning.
Authors:Andersen NS, Bornhauser M, Gramatzki M, Dreger P, Vitek A, Karas M, Michallet M, Moreno C, van Gelder M, Henseler A, de Wreede LC, Schonland S, Kroger N, Schetelig J
Institution:BMT Unit Department of Hematology, Rigshospitalet, Copenhagen, Denmark. Dresden, Fetscherstrasse 74, 01307, Dresden, Germany. Schleswig-Holstein, Kiel, Germany. Germany. Czech Republic. Republic. Maastricht, The Netherlands. The Netherlands. The Netherlands. Germany. Germany.
Journal:J Cancer Res Clin Oncol. 2019 Nov;145(11):2823-2834. doi: 10.1007/s00432-019-03014-x. Epub 2019 Aug 29.

2:Adverse drug events associated with ibrutinib for the treatment of elderly patients with chronic lymphocytic leukemia: A systematic review and meta-analysis of randomized trials.
Authors:Zhou Y, Lu H, Yang M, Xu C
Institution:Department of Hematology, Jingzhou First People's Hospital, The First Affiliated Hospital of Yangtze University, Jingzhou.; Department of Cardiology, Jingzhou Central Hospital, The Second Clinical Medical College, Yangtze University, Jingzhou, Hubei, People's Republic of China.
Journal:Medicine (Baltimore). 2019 Aug;98(33):e16915. doi: 10.1097/MD.0000000000016915.

3:Ibrutinib-Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia.
Authors:Shanafelt TD, Wang XV, Kay NE, Hanson CA, O'Brien S, Barrientos J, Jelinek DF, Braggio E, Leis JF, Zhang CC, Coutre SE, Barr PM, Cashen AF, Mato AR, Singh AK, Mullane MP, Little RF, Erba H, Stone RM, Litzow M, Tallman M
Institution:From Stanford University, Stanford (T.D.S., S.E.C.), the University of California, Irvine, Medical Center, Orange (S.O.), and Kaiser Permanente National Cancer Institute Community Oncology Research Program (NCORP)-Permanente Medical Group, Oakland (C.C.Z.) - all in California; Dana-Farber Cancer Institute, Boston (X.V.W., R.M.S.); Mayo Clinic, Rochester (N.E.K., C.A.H., J.F.L., M.L.), and Minnesota Oncology, Burnsville (A.K.S.) - both in Minnesota; Northwell Health Cancer Institute, Donald and Barbara Zucker School of Medicine at Hofstra-Northwell, Lake Success (J.B.), and University of Rochester, Rochester (P.M.B.) - both in New York; Mayo Clinic, Phoenix, AZ (D.F.J., E.B.); Washington University School of Medicine, St. Louis (A.F.C.); Memorial Sloan Kettering Cancer Center, New York (A.R.M., M.T.); Aurora Cancer Care, West Allis, WI (M.P.M.); National Cancer Institute, Bethesda, MD (R.F.L.); and the University of Alabama, Tuscaloosa (H.E.).
Journal:N Engl J Med. 2019 Aug 1;381(5):432-443. doi: 10.1056/NEJMoa1817073.

4:Obinutuzumab and ibrutinib induction therapy followed by a minimal residual disease-driven strategy in patients with chronic lymphocytic leukaemia (ICLL07 FILO): a single-arm, multicentre, phase 2 trial.
Authors:Michallet AS, Dilhuydy MS, Subtil F, Rouille V, Mahe B, Laribi K, Villemagne B, Salles G, Tournilhac O, Delmer A, Portois C, Pegourie B, Leblond V, Tomowiak C, de Guibert S, Orsini F, Banos A, Carassou P, Cartron G, Fornecker LM, Ysebaert L, Dartigeas C, Truchan Graczyk M, Vilque JP, Aurran T, Cymbalista F, Lepretre S, Levy V, Nguyen-Khac F, Le Garff-Tavernier M, Aanei C, Ticchioni M, Letestu R, Feugier P
Institution:Department of Hematology, Centre Leon Berard, Lyon, France. Electronic address: anne-sophie.michallet@lyon.unicancer.fr.; Department of Hematology, CHU Bordeaux, Bordeaux, France.; Department of Biostatistics, Hospices Civils de Lyon, Lyon, France.; Department of Hematology, CHU Montpellier, Montpellier, France.; Department of Hematology, CHU Nantes, Nantes, France.
Journal:Lancet Haematol. 2019 Sep;6(9):e470-e479. doi: 10.1016/S2352-3026(19)30113-9. Epub 2019 Jul 16.

5:Chronic lymphocytic leukaemia: from genetics to treatment.
Authors:Bosch F, Dalla-Favera R
Institution:Department of Haematology, University Hospital Vall d'Hebron, Autonomous University, Barcelona, Spain. fbosch@vhio.net. (VHIO), Barcelona, Spain. fbosch@vhio.net. fbosch@vhio.net.
Journal:Nat Rev Clin Oncol. 2019 Nov;16(11):684-701. doi: 10.1038/s41571-019-0239-8.

6:Ibrutinib plus fludarabine, cyclophosphamide, and rituximab as initial treatment for younger patients with chronic lymphocytic leukaemia: a single-arm, multicentre, phase 2 trial.
Authors:Davids MS, Brander DM, Kim HT, Tyekucheva S, Bsat J, Savell A, Hellman JM, Bazemore J, Francoeur K, Alencar A, Shune L, Omaira M, Jacobson CA, Armand P, Ng S, Crombie J, LaCasce AS, Arnason J, Hochberg EP, Takvorian RW, Abramson JS, Fisher DC, Brown JR
Institution:Dana-Farber Cancer Institute, Department of Medical Oncology, Boston, MA, USA. Electronic address: matthew_davids@dfci.harvard.edu. School of Public Health, Department of Biostatistics, Boston, MA, USA. School of Public Health, Department of Biostatistics, Boston, MA, USA. Hematology and Oncology, Miami, FL, USA. Westwood, KS, USA. USA.
Journal:Lancet Haematol. 2019 Aug;6(8):e419-e428. doi: 10.1016/S2352-3026(19)30104-8. Epub 2019 Jun 14.

7:Ibrutinib discontinuation in patients with relapsed or refractory chronic lymphocytic leukemia treated in a compassionate use program: A report from the Polish Adult Leukemia Study Group (PALG).
Authors:Iskierka-Jazdzewska E, Pula B, Szeremet A, Hus M, Golos A, Holojda J, Piszczek W, Steckiewicz P, Wojciechowska M, Zaucha JM, Warzocha K, Jamroziak K
Institution:Department of Hematology, Copernicus Memorial Hospital, Lodz, Poland. Warszawa, Poland. Wroclaw Medical University, Poland. of Lublin, Poland. Warszawa, Poland. Warszawa, Poland. Warszawa, Poland.
Journal:Adv Clin Exp Med. 2019 Aug;28(8):1051-1057. doi: 10.17219/acem/99911.

8:Ibrutinib and Venetoclax for First-Line Treatment of CLL.
Authors:Jain N, Keating M, Thompson P, Ferrajoli A, Burger J, Borthakur G, Takahashi K, Estrov Z, Fowler N, Kadia T, Konopleva M, Alvarado Y, Yilmaz M, DiNardo C, Bose P, Ohanian M, Pemmaraju N, Jabbour E, Sasaki K, Kanagal-Shamanna R, Patel K, Jorgensen J, Garg N, Wang X, Sondermann K, Cruz N, Wei C, Ayala A, Plunkett W, Kantarjian H, Gandhi V, Wierda W
Institution:From the Departments of Leukemia (N.J., M. Keating, P.T., A.F., J.B., G.B., K.T., Z.E., T.K., M. Konopleva, Y.A., M.Y., C.D., P.B., M.O., N.P., E.J., K. Sasaki, K. Sondermann, N.C., C.W., A.A., H.K., W.W.), Lymphoma and Myeloma (N.F.), Hematopathology (R.K.-S., K.P., J.J.), Diagnostic Radiology (N.G.), Biostatistics (X.W.), and Experimental Therapeutics (W.P., V.G.), University of Texas M.D. Anderson Cancer Center, Houston.
Journal:N Engl J Med. 2019 May 30;380(22):2095-2103. doi: 10.1056/NEJMoa1900574.

9:Tailored Treatment Strategies for Chronic Lymphocytic Leukemia in a Rapidly Changing Era.
Authors:Brander D, Islam P, Barrientos JC
Institution:1 Duke University Health System, Duke Cancer Institute, Durham, NC. Hofstra/Northwell, Feinstein Institute for Medical Research, CLL Research and Treatment Program, New Hyde Park, NY.
Journal:Am Soc Clin Oncol Educ Book. 2019 Jan;39:487-498. doi: 10.1200/EDBK_238735. Epub 2019 May 17.

10:Hodgkin lymphoma transformation of chronic lymphocytic leukemia-A real life data from the Polish Lymphoma Research Group.
Authors:Drozd-Sokolowska J, Zaucha JM, Zoltak T, Jamroziak K, Grzybowska-Izydorczyk O, Witkowska M, Waszczuk-Gajda A, Kazmierczak M, Szczepaniak A, Subocz E, Knopinska-Posluszny W, Holojda J, Kopinska A, Hus I, Rybka J, Wolowiec D, Kwiatkowski J, Halaburda K, Smolewski P, Giebel S, Wiktor-Jedrzejczak W
Institution:Department of Hematology, Oncology and Internal Diseases, Medical University of Warsaw, Warsaw, Poland.; Department of Hematology and Transplantology, Medical University of Gdansk, Gdansk, Poland.; Educational Research Institute, Warsaw, Poland.; Department of Hematology, Institute of Hematology and Transfusion Medicine, Warsaw, Poland.; Department of Experimental Hematology, Medical University of Lodz, Lodz, Poland.
Journal:Hematol Oncol. 2019 Oct;37(4):383-391. doi: 10.1002/hon.2624. Epub 2019 Jun 14.

11:Venetoclax in the treatment of chronic lymphocytic leukemia.
Authors:Korycka-Wolowiec A, Wolowiec D, Kubiak-Mlonka A, Robak T
Institution:a Department of Hematology , Medical University of Lodz , Lodz , Poland.
Journal:Expert Opin Drug Metab Toxicol. 2019 May;15(5):353-366. doi: 10.1080/17425255.2019.1606211. Epub 2019 Apr 25.

12:Low-dose fludarabine and cyclophosphamide combined with standard dose rituximab (LD-FCR) is an effective and safe regimen for elderly untreated patients with chronic lymphocytic leukemia: The Israeli CLL study group experience.
Authors:Herishanu Y, Tadmor T, Braester A, Bairey O, Aviv A, Rahimi-Levene N, Fineman R, Levi I, Yuklea M, Ruchlemer R, Shvidel L, Polliack A
Institution:Department of Hematology, Tel-Aviv Sourasky Medical Center, Tel-Aviv, Israel. Galilee, Nahariya, Israel. University, Beer Sheba, Israel. Medical School, Jerusalem, Israel.
Journal:Hematol Oncol. 2019 Apr;37(2):185-192. doi: 10.1002/hon.2580. Epub 2019 Mar 12.

13:Relevance of TP53 for CLL diagnostics.
Authors:Catherwood MA, Gonzalez D, Donaldson D, Clifford R, Mills K, Thornton P
Institution:Haematology Department, Belfast Health and Social Care Trust, Belfast, UK mark.catherwood@belfasttrust.hscni.net. Belfast, UK. Belfast, UK.
Journal:J Clin Pathol. 2019 May;72(5):343-346. doi: 10.1136/jclinpath-2018-205622. Epub 2019 Feb 2.

14:Effectiveness of the Combination of Rituximab and Standard Chemotherapeutic Regimens in Previously Untreated Patients with Chronic Lymphocytic Leukaemia in Real-Life: Results from a Noninterventional Study (CILI Study).
Authors:Szasz R, Altai E, Pal K, Dombi P, Ivanyi J, Jakucs J, Joni N, Illes A, Tarkanyi I, Szerafin L, Nagy Z, Farkas P, Nagy A, Piukovics K, Ujj G, Schneider T
Institution:Division of Hematology, Department of Internal Medicine, Faculty of Medicine, University of Debrecen, Nagyerdei krt. 98, Debrecen, 4032, Hungary. szaszr@med.unideb.hu.; Veszprem County Csolnoky Ferenc Hospital, Korhaz u. 1, Veszprem, 8200, Hungary.; Fejer County Szent Gyorgy Hospital, Seregelyesi ut 3, Szekesfehervar, 8000, Hungary.; Department of Hematology, Szent Borbala Hospital, Dozsa Gyorgy ut 77, Tatabanya, 2800, Hungary.; Department of Hematology, Vas County Markusovszky Hospital, Markusovszky L. u. 5, Szombathely, 9700, Hungary.
Journal:Pathol Oncol Res. 2019 Apr;25(2):535-540. doi: 10.1007/s12253-018-0474-9. Epub 2018 Oct 25.

15:Updated results from the phase 3 HELIOS study of ibrutinib, bendamustine, and rituximab in relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma.
Authors:Fraser G, Cramer P, Demirkan F, Silva RS, Grosicki S, Pristupa A, Janssens A, Mayer J, Bartlett NL, Dilhuydy MS, Pylypenko H, Loscertales J, Avigdor A, Rule S, Villa D, Samoilova O, Panagiotidis P, Goy A, Pavlovsky MA, Karlsson C, Hallek M, Mahler M, Salman M, Sun S, Phelps C, Balasubramanian S, Howes A, Chanan-Khan A
Institution:Juravinski Cancer Centre, McMaster University, Hamilton, ON, Canada. fraserg@HHSC.CA. Study Group, University of Cologne, Cologne, Germany. University, Katowice, Poland. Hospital Brno, Jihlavska, Brno, Czech Republic. USA. Ukraine. Center, Tel-Hashomer and Sackler School of Medicine, University of Tel-Aviv, Tel-Aviv, Israel.
Journal:Leukemia. 2019 Apr;33(4):969-980. doi: 10.1038/s41375-018-0276-9. Epub 2018 Oct 12.

For a FREE PREVIEW of the Medifocus Guidebook on Chronic Lymphocytic Leukemia click here

To purchase a copy of the COMPLETE Medifocus Guidebook on Chronic Lymphocytic Leukemia click here

To subscribe to additional FREE Medifocus Digest Alert on other disease/condition areas click here

  
Get the Medifocus Guidebook on Chronic Lymphocytic Leukemia...
at a Special 20% Discount


Medifocus Guidebook on Chronic Lymphocytic Leukemia

Updated: January 6, 2020
194 Pages

This one of a kind Guidebook offers:

  • Answers to your critical health questions including the latest treatments, clinical trials, and expert research.
     
  • High Quality, Professional level information you can trust and understand culled from the latest peer-reviewed journals.
     
  • Timely, up to date content with free guidebook updates for 1 year.
     
  • A unique resource to find leading experts, institutions, and support organizations including contact information and hyperlinks.
     
  • Over 130,000 Guidebooks Sold
     
  • 100% Risk Free Money Back Guarantee



ORDER THE GUIDEBOOK

The Medifocus Guidebook on Chronic Lymphocytic Leukemia is available in the following two convenient formats:

PRINTED GUIDEBOOK

Soft-cover book that is available for immediate shipping via either U.S. Priority Mail or International AirMail (outside the U.S.).

  • Regular List Price = $36.95
  • Less 20% Discount = - $7.40
  • Discounted Price = $29.55(excluding shipping & handling)

Order the Printed Guidebook

DIGITAL GUIDEBOOK

Available for immediate download as a PDF document.

  • Regular List Price = $27.95
  • Less 20% Discount = - $5.60
  • Discounted Price = $22.35

Order the Digital Guidebook



Order by Phone

Call Toll Free in the U.S.
1-800-965-3002

From Outside the U.S.
1-301-649-9300

You can also receive a 20% discount when you order your Guidebook by phone.

To receive your 20% discount, simply mention the Discount Coupon Code below to the customer service representative taking your order.

Discount Coupon Code for
Phone Orders

CL43618829

Coupon Expires: May 6, 2020



What Our Customers Are Saying...

"I was recently diagnosed with CLL and searched all over the Web for information. I found the MediFocus Guidebook on Chronic Lymphocytic Leukemia to be a very useful resource. The information about chemotherapy was most important to me as well as recent studies concerning general treatments for this condition. The most valuable information was contained in the extensive references listed which were easy to access with a simple 'mouse' click. You are welcome to use my name as a reference."
G.C.
Coedpoeth, United Kingdom



  
Medifocus Digest Alert is published by Medifocus, Inc.
3809 Clarks Lane, Suite 100, Baltimore, MD 21215 USA
Copyright © 2020 Medifocus, Inc. All rights reserved.